AU2013251309B2 - Modified antibody regions and uses thereof - Google Patents

Modified antibody regions and uses thereof Download PDF

Info

Publication number
AU2013251309B2
AU2013251309B2 AU2013251309A AU2013251309A AU2013251309B2 AU 2013251309 B2 AU2013251309 B2 AU 2013251309B2 AU 2013251309 A AU2013251309 A AU 2013251309A AU 2013251309 A AU2013251309 A AU 2013251309A AU 2013251309 B2 AU2013251309 B2 AU 2013251309B2
Authority
AU
Australia
Prior art keywords
region
antibody
modified
amino acid
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013251309A
Other languages
English (en)
Other versions
AU2013251309A1 (en
Inventor
Hwai Wen Chang
Gerhard Frey
Jay M. Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of AU2013251309A1 publication Critical patent/AU2013251309A1/en
Application granted granted Critical
Publication of AU2013251309B2 publication Critical patent/AU2013251309B2/en
Priority to AU2017225111A priority Critical patent/AU2017225111B2/en
Assigned to BIOATLA, LLC reassignment BIOATLA, LLC Request to Amend Deed and Register Assignors: BIOATLA LLC
Priority to AU2019202229A priority patent/AU2019202229B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2013251309A 2012-04-27 2013-04-26 Modified antibody regions and uses thereof Active AU2013251309B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017225111A AU2017225111B2 (en) 2012-04-27 2017-09-08 Modified antibody regions and uses thereof
AU2019202229A AU2019202229B2 (en) 2012-04-27 2019-04-01 Modified antibody regions and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639729P 2012-04-27 2012-04-27
US61/639,729 2012-04-27
PCT/US2013/038538 WO2013163630A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017225111A Division AU2017225111B2 (en) 2012-04-27 2017-09-08 Modified antibody regions and uses thereof

Publications (2)

Publication Number Publication Date
AU2013251309A1 AU2013251309A1 (en) 2014-10-30
AU2013251309B2 true AU2013251309B2 (en) 2017-06-22

Family

ID=49483948

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013251309A Active AU2013251309B2 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof
AU2017225111A Active AU2017225111B2 (en) 2012-04-27 2017-09-08 Modified antibody regions and uses thereof
AU2019202229A Active AU2019202229B2 (en) 2012-04-27 2019-04-01 Modified antibody regions and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017225111A Active AU2017225111B2 (en) 2012-04-27 2017-09-08 Modified antibody regions and uses thereof
AU2019202229A Active AU2019202229B2 (en) 2012-04-27 2019-04-01 Modified antibody regions and uses thereof

Country Status (13)

Country Link
US (2) US20150065690A1 (enExample)
EP (2) EP3470433B1 (enExample)
JP (1) JP6470170B2 (enExample)
KR (2) KR20200037434A (enExample)
CN (1) CN104428317B (enExample)
AU (3) AU2013251309B2 (enExample)
BR (1) BR112014026740B1 (enExample)
CA (1) CA2871807C (enExample)
HK (1) HK1207654A1 (enExample)
IN (1) IN2014DN08721A (enExample)
MX (2) MX382840B (enExample)
RU (1) RU2014147741A (enExample)
WO (1) WO2013163630A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015175375A1 (en) * 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
CR20180445A (es) * 2016-03-14 2019-02-08 Univ Oslo Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
AU2018226857B2 (en) 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
JP7341900B2 (ja) 2017-03-03 2023-09-11 オブシディアン セラピューティクス， インコーポレイテッド 免疫療法のためのｃｄ１９組成物及び方法
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
NZ775959A (en) * 2018-10-31 2022-08-26 Bioatla Inc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
AU2020205073A1 (en) * 2019-01-03 2021-08-19 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP4014050A1 (en) 2019-08-12 2022-06-22 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20230183353A1 (en) * 2020-05-21 2023-06-15 Zydus Lifesciences Limited Fc variant and preparation thereof
WO2021234160A2 (en) 2020-05-22 2021-11-25 Formycon Ag Ace2 fusion proteins and uses thereof
EP4204091A2 (en) 2020-10-29 2023-07-05 Formycon AG Ace2 fusion proteins and uses thereof
EP4301333A2 (en) 2021-03-03 2024-01-10 Formycon AG Formulations of ace2 fc fusion proteins
EP4437112A1 (en) 2021-11-24 2024-10-02 Formycon AG Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
EP4386084A1 (en) 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037000A1 (en) * 2003-01-09 2005-02-17 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2006053301A2 (en) * 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
DK1562972T3 (da) * 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003280247A1 (en) 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CA2545603A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
CN103172731A (zh) * 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
CA2618681C (en) * 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
JP2009511067A (ja) * 2005-10-14 2009-03-19 メディミューン，エルエルシー 抗体ライブラリーの細胞提示
PL2808343T3 (pl) * 2007-12-26 2019-11-29 Xencor Inc Warianty Fc ze zmienionym wiązaniem do FcRn
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
WO2010085682A2 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
EP3252072A3 (en) * 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US8483058B2 (en) 2010-08-17 2013-07-09 Qualcomm Incorporated Systems and methods for traffic policing
US9035007B2 (en) 2011-07-15 2015-05-19 Basell Poliolefine Italia S.R.L. Polyolefin strap comprising a random copolymer of propylene with 1-hexene
CN113061993A (zh) * 2011-09-30 2021-07-02 中外制药株式会社 离子浓度依赖性结合分子文库
JP2015506687A (ja) * 2012-01-19 2015-03-05 セラピューティック プロテインズ インターナショナル， エルエルシー 抗−ｃｄ２０抗体リツキシマブの安定化

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037000A1 (en) * 2003-01-09 2005-02-17 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2006053301A2 (en) * 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn

Also Published As

Publication number Publication date
CN104428317B (zh) 2018-08-28
EP3470433B1 (en) 2025-12-03
AU2019202229B2 (en) 2021-02-11
EP3470433C0 (en) 2025-12-03
IN2014DN08721A (enExample) 2015-05-22
RU2014147741A (ru) 2016-06-20
MX360368B (es) 2018-10-29
AU2013251309A1 (en) 2014-10-30
US10954288B2 (en) 2021-03-23
AU2017225111B2 (en) 2019-01-03
CN104428317A (zh) 2015-03-18
CA2871807A1 (en) 2013-10-31
AU2019202229A1 (en) 2019-04-18
BR112014026740A2 (pt) 2017-06-27
US20180186863A1 (en) 2018-07-05
MX382840B (es) 2025-03-13
JP2015515497A (ja) 2015-05-28
BR112014026740B1 (pt) 2022-10-04
EP2841458A1 (en) 2015-03-04
HK1207654A1 (en) 2016-02-05
AU2017225111A1 (en) 2017-09-28
KR20200037434A (ko) 2020-04-08
JP6470170B2 (ja) 2019-02-13
US20150065690A1 (en) 2015-03-05
EP2841458A4 (en) 2015-09-16
MX2014012978A (es) 2015-02-05
EP3470433A1 (en) 2019-04-17
BR112014026740A8 (pt) 2021-06-15
CA2871807C (en) 2022-10-04
KR20150008082A (ko) 2015-01-21
WO2013163630A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
AU2019202229B2 (en) Modified antibody regions and uses thereof
CA2834992C (en) Therapeutic canine immunoglobulins and methods of using the same
US9580496B2 (en) Therapeutic canine immunoglobulins and methods of using same
US20210054049A1 (en) Variant domains for multimerizing proteins and separation thereof
RU2715606C2 (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
WO2023061390A1 (en) Treatment of ige-mediated diseases
US20160340422A1 (en) Bifunctional fusion protein, preparation method therefor, and use thereof
JP7127859B2 (ja) キメラタンパク質を用いたアレルギー疾患の治療
HK40009281A (en) Modified antibody regions and uses thereof
TW202509059A (zh) 具有經修飾Ｆｃ區之雙特異性抗假單胞菌抗體及其使用方法
BR122024006370A2 (pt) Polipeptídeo, seu uso, composição farmacêutica, kit, igg modificada, vetor, célula isolada, molécula de fusão, e seu método de fabricação

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: BIOATLA, LLC

Free format text: FORMER NAME(S): BIOATLA LLC